Biogen Idec commissioned Charles River Associates to examine how access to innovative treatments for multiple sclerosis (MS) varies across European countries, the factors explaining this, and the policy lessons that can be drawn. MS is a disorder of the central nervous system (brain and spinal cord) affecting over 500,000 Europeans. CRA found that significant inequalities in access to MS treatments persist in 2013. To download the PDF version of this report click the link below.
When simple data patterns are not enough: The economic complexity behind non-competes in the healthcare industry
The Federal Trade Commission (FTC), Department of Justice (DOJ), and state regulators have publicly stated that non-compete agreements (NCAs) are an...